Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Alnylam Pharmaceuticals (ALNY) PT Raised to $128 at BMO Capital
May 1, 2019 12:59 PM EDTBMO Capital analyst Do Kim raised the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $128.00 (from $126.00) while maintaining a Outperform rating following Q1 results.
The analyst commented, "We raise our Onpattro projections and target price to $128 from $126, as 1Q19 sales beat our and... More
Alnylam Pharma (ALNY) Tops Q1 EPS by 65c
May 1, 2019 8:06 AM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.42), $0.65 better than the analyst estimate of ($2.07). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $23.65 million.
2019 Updated Financial Guidance
Alnylam is updating its 2019 annual non-GAAP R&D... More
